Overview
ExpreS2ion Biotech Holding AB, based in Sweden, operates within the biotechnology sector, primarily focusing on the development of vaccine technologies and immunotherapies. The company leverages its proprietary ExpreS2 platform, a stable and adaptable protein expression system derived from insect cells, to facilitate the discovery and production of complex proteins vital to developing new vaccines and treatments. A key project includes their work on a breast cancer vaccine candidate, along with ongoing collaborations on various infectious disease vaccines, such as their notable involvement in developing a COVID-19 vaccine. Their approach underlines a commitment to enhancing vaccine development and response rates, aligning with global health needs and advancing medical research in immunotherapy.
AI+ Ask Fintel’s AI assistant about ExpreS2ion Biotech Holding AB (publ).
Thinking about good questions…
Basic Stats
The share price of ExpreS2ion Biotech Holding AB (publ) as of 1 September 2025 is 22,50 kr / share. This is a decrease of -0.66% from the prior week. The market cap (or net worth) of ExpreS2ion Biotech Holding AB (publ) as of 1 September 2025 is 59,81 kr MM.
The Factor Analysis chart (below right) shows a view of ExpreS2ion Biotech Holding AB (publ) from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 59.81 MM |
| EV | 11.54 MM |
| Shares Out. | 2.66 MM |
| Earnings Date | |
| EPS (TTM) | -17.75 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 2,291.07 % |
| Volatility (1 yr) | 35.97 |
| Beta | -24.16 |
| Sharpe Ratio (1 yr) | 0.64 |
| Sortino Ratio (1 yr) | 51.12 |
| PE Ratio | -1.27 |
| Price/Book | 1.41 |
| Price/TBV | 1.47 |
| Book/Market | 0.71 |
| EBIT/EV | -4.92 |
| EBIT(3yr avg)/EV | -7.34 |
| ROA | -0.50 |
| ROE | -0.86 |
| ROIC | -1.07 |
| CROIC | -0.45 |
| OCROIC | -1.21 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 35.00 /100 |
| Profitability | 2.47 /100 |
| Quality Score | 20.59 /100 |
| Value Score | 0.26 /100 |
| Momentum Score | 18.82 /100 |
| Stability (Low Vol) Score | |
| Analyst Sentiment | 60.16 /100 |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 1.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for ExpreS2ion Biotech Holding AB (publ) is 76,50 kr. The forecasts range from a low of 75,75 kr to a high of 78,75 kr. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for ExpreS2ion Biotech Holding AB (publ). An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-03-04 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2023-05-16 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2023-12-20 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2023-05-17 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2024-07-11 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2023-12-19 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2024-11-03 | PARETO SECURITIES AS | Buy | Buy | Maintains |
